Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
150%(9 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_4
1
11%
Ph phase_3
7
78%
Ph phase_2
1
11%

Phase Distribution

0

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
7(77.8%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Terminated(3)

Detailed Status

Completed6
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (11.1%)
Phase 37 (77.8%)
Phase 41 (11.1%)

Trials by Status

terminated333%
completed667%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

NCT05295459
terminatedphase_2

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
completedphase_3

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

NCT05219968
terminatedphase_3

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
completedphase_3

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

NCT02735044
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05295459Phase 3

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

Completed
NCT04564339Phase 2

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Terminated
NCT05219968Phase 3

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

Completed
NCT03434119Phase 3

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Terminated
NCT02735044Phase 3

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

Completed
NCT03713684Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Terminated
NCT02320721Phase 3

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Completed
NCT02897349Phase 3

Linagliptin Add-on to Insulin Background Therapy

Completed
NCT02451137Phase 4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Completed

All 9 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
9